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Atherosclerosis is a chronic inflammatory disease of the vasculature that causes 
significant morbidity and mortality from myocardial infarction, stroke, and peripheral 
vascular disease. Landmark clinical trials revealed that mineralocorticoid receptor (MR) 
antagonists improve outcomes in cardiovascular patients. Conversely, enhanced MR 
activation by the hormone aldosterone is associated with increased risk of MI, stroke, 
and cardiovascular death. This review summarizes recent advances in our understand-
ing of the role of aldosterone and the MR in the pathogenesis of vascular inflammation 
and atherosclerosis as it proceeds from risk factor-induced endothelial dysfunction and 
inflammation to plaque formation, progression, and ultimately rupture with thrombosis, 
the cause of acute ischemia. The role of the MR in converting cardiac risk factors 
into endothelial dysfunction, in enhancing leukocyte adhesion and infiltration into the 
vasculature, in promoting systemic inflammation and vascular oxidative stress, and in 
plaque destabilization and thrombosis are discussed. A greater understanding of the 
mechanisms by which the MR promotes atherosclerosis has substantial potential to 
identify novel treatment targets to improve cardiovascular health and decrease mortality.
Keywords: mineralocorticoid receptors, aldosterone, atherosclerosis/CAD, vascular inflammation, 
mineralocorticoid receptor antagonists
introduction
Pathophysiology of Atherosclerosis
Atherosclerosis is a vascular inflammatory condition that is the primary cause of myocardial infarction 
(MI), stroke, and limb ischemia. Through substantial research efforts, what was originally thought of 
as simply a buildup of cholesterol in the arteries is now known to be a chronic inflammatory process 
involving multiple interacting cell types [reviewed in Ref. (1, 2)]. Briefly, atherosclerosis is triggered 
by risk factors, such as hyperlipidemia, diabetes, and hypertension, which contribute to injury of the 
inner endothelial layer of blood vessels. Damage to the endothelium promotes endothelial expres-
sion of adhesion molecules, which mediate leukocyte adhesion and migration through the activated 
endothelium into the underlying tissue. Once in the sub-endothelial space, activated macrophages 
engulf lipid particles, become foam cells, and release cytokines that attract additional leukocytes. 
Vascular smooth muscle cells (SMCs) also become activated, in part by factors released from plaque 
leukocytes, and migrate into the plaque and contribute to a fibrotic cap covering the highly thrombo-
genic core of lipids and inflammatory cells. This cascade of events forms the mature atherosclerotic 
plaque. Inflammatory cells and plaque SMCs secrete matrix metalloproteases (MMPs), which 
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destabilize the fibrous cap and predispose the plaque to rupture. 
Ruptured plaques induce thrombus formation that occludes blood 
flow to cardiac tissue causing MI, to the brain causing stroke, or to 
the peripheral vasculature causing limb ischemia.
Mineralocorticoid Receptors and 
Atherosclerosis
The mineralocorticoid receptor (MR) is well-known as a regulator 
of blood pressure in the kidney, where it promotes sodium retention 
when activated by its hormone ligand aldosterone (Aldo). MR can 
also be activated by other mechanisms, including glucocorticoids 
in tissues lacking the cortisol-inactivating enzyme 11beta-hydrox-
ysteroid dehydrogenase-2 and ligand-independent activation by 
mechanisms still under investigation. MR-independent effects of 
Aldo have also been reported. These additional mechanisms will 
not be discussed as they have been reviewed elsewhere [reviewed 
in Ref. (3–6)] and are beyond the scope of this review that focuses 
specifically on the role of non-renal MR in the pathogenesis of 
atherosclerosis. In addition to its effects on renal sodium han-
dling, clinical studies suggest a more direct role for the MR in 
cardiovascular pathology in humans. In the RALES, EPHESUS, 
and EMPHASIS heart failure trials, MR antagonists decreased 
cardiovascular morbidity and mortality and prolonged survival 
when compared with placebo controls (7, 8). The observed benefits 
of MR inhibition were out of proportion to modest decreases in 
blood pressure, suggesting that MR blockade may exert beneficial 
cardiovascular effects in tissues outside the kidney. Indeed, Milliez 
et al. (9) demonstrated that individuals with abnormal MR activa-
tion due to hyperaldosteronism experienced stroke, MI, and atrial 
fibrillation at 4, 6, and 12 times the rate of blood pressure-matched 
controls. Higher plasma Aldo, even within the normal range, is 
associated with a significantly increased risk of MI, stroke, and 
cardiovascular death in patients with coronary artery disease (10) 
and is an independent risk factor for the progression of carotid 
atherosclerotic plaques (11). These data suggest an extra-renal 
role for the MR in the pathophysiology of atherosclerosis that may 
contribute substantially to cardiovascular morbidity and mortality.
Pre-clinical data in animal models also support a role for 
extra-renal MRs in atherogenesis. The apolipoprotein E knockout 
(ApoE−/−) mouse model rapidly develops atherosclerotic plaques 
that mimic the human pathology. Using this model, Tikellis et al. 
(12) investigated effects of renin–angiotensin–aldosterone system 
(RAAS) activation by low-sodium intake on the development of 
atherosclerosis. Low-sodium intake accelerated atherosclerotic 
lesion progression threefold compared to normal-salt controls. 
The pro-atherogenic effect was RAAS dependent, as it was attenu-
ated by treatment with an angiotensin-converting enzyme inhibi-
tor. More recently, McGraw et al. (13) demonstrated that low-dose 
Aldo infusion into ApoE−/− mice increased atherosclerotic plaque 
burden and lipid content in the aortic root and arch after 4 weeks 
on a high-fat diet, compared to vehicle-infused controls. Aldo 
increased atherogenesis without a change in blood pressure. 
Aldo mainly promoted early atherosclerosis, as at 8  weeks the 
plaque size and lipid content in the aortic root had equalized 
between the two groups. Conversely, treatment with the MR 
antagonist eplerenone attenuated early (14), but not advanced, 
plaque development in ApoE−/− mice (15, 16). In short, abundant 
data support a blood pressure-independent contribution of MR 
and Aldo to the pathogenesis of atherosclerosis in human and in 
animal models. This review summarizes recent advances in our 
understanding of the mechanisms by which the MR contributes 
to atherosclerosis by participating in initial endothelial injury, 
vascular inflammation, dysfunction of inflammatory cells, and 
the development of unstable plaques predisposed to thrombosis.
MR in the vascular endothelium 
Contributes to endothelial Cell Damage 
and Dysfunction Caused by 
Cardiovascular Risk Factors
Atherosclerosis begins with dysfunction of the vascular endothe-
lium. Healthy endothelial cells (ECs) contribute to vasodilation 
by producing nitric oxide via endothelial nitric oxide synthase 
(eNOS) activity. Nitric oxide production is impaired early in 
atherogenesis, and the downstream effects of this can be measured 
in vivo by tonometry and flow-mediated vasodilation or ex vivo by 
quantifying achetylcholine-induced vasodilation of arterial rings. 
Aldo and vascular MR have been recently implicated in the devel-
opment of endothelial dysfunction in humans with cardiovascular 
risk factors and in corresponding animal models. Hypertensive 
African-Americans had impaired endothelial function, as meas-
ured by pulse arterial tonography and by ex vivo studies of adipose 
vessels, which was improved with spironolactone treatment. 
Conversely, normotensive subjects had impaired endothelial 
function after Aldo administration, which was also prevented 
by spironolactone (17). Hypertensive subjects had an associated 
decrease in arteriolar glucose-6-phosphate dehydrogenase (G6PD) 
activity compared to non-hypertensives. A potential mechanism 
is suggested by a prior study demonstrating that Aldo treatment 
of bovine ECs in vitro and of mice in vivo decreases EC G6PD 
expression, resulting in excessive production of reactive oxygen 
species [ROS (18)]. In another study, treatment of diabetics with 
spironolactone improved coronary flow reserve, as measured by 
cardiac PET scan, compared to subjects treated with hydrochloro-
thiazide to achieve the same blood pressure (19). Thus, in patients 
with risk factors including hypertension and diabetes, endothelial 
dysfunction appears to be MR dependent (Figure 1).
Studies in animal models also support that the role of the MR 
in endothelial function depends on the health and integrity of the 
endothelium. Heylen et al. (20) found that arterioles from healthy 
male Wistar rats dilate in response to Aldo placed in the buffer 
bath, with even greater vasodilation when Aldo was administered 
intraluminally to directly target the endothelium. However, when 
the endothelium was denuded, Aldo instead induced vasocon-
striction. This suggests a vasodilatory response in normal, healthy 
endothelium, and a vasoconstriction response (likely mediated 
by SMC–MR) when the endothelium is damaged or removed. To 
specifically interrogate the role of endothelial MR in vasodilatory 
function, several groups have used transgenic animal models with 
MR specifically deleted from ECs. Most studies demonstrated 
that EC–MR deletion does not alter endothelium-dependent 
relaxation in healthy aorta (21), mesentery, and coronary vascular 
beds (22) as measured using myographic techniques [although 
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one study demonstrated decreased vasodilation in the aorta from 
EC–MR knockout mice (23)]. However, in animal models of car-
diovascular risk factors, Aldo and the MR (likely in ECs) appear 
to contribute to the development of endothelial dysfunction. In 
a diet-induced obesity model, impaired endothelial-dependent 
vasodilation is prevented by MR inhibition with eplerenone or 
deletion of EC–MR (21). Similarly, endothelial dysfunction in a 
rat streptozotocin-induced diabetes model is MR dependent, as 
it was inhibited by spironolactone (24). In the stroke-prone spon-
taneously hypertensive rat model, spironolactone significantly 
improved endothelial function in the middle cerebral artery and 
reduced post-ischemia stroke infarct size (25). Finally, EC–MR 
knockout mice had improved endothelial function after 2 weeks 
of angiotensin-II-induced hypertension compared to MR-intact 
mice (22). In the same study, EC–MR was also found to contrib-
ute to coronary vasoconstriction in response to endothelin-1 
FiGURe 1 | Aldo and MR in vascular inflammation. (1) Aldo induces systemic inflammation in the setting of cardiovascular risk factors. (2) In response to 
endothelial damage, Aldo acts on EC–MR to induce cytokine and adhesion molecule expression. (3) Cytokines produced by the endothelium and underlying SMCs 
induce EC adhesion molecule expression and leukocyte recruitment, adhesion, and transmigration. (4) Aldo also acts on EC–MR to induce rearrangement of the 
actin cytoskeleton, possibly facilitating leukocyte transmigration. (5) Myeloid MR induces ROS production and macrophage activation and polarization to the M1 
phenotype. (6) MR induces T cell expression of homing markers and differentiation to the Th17 subset. (7) Aldo activation of neutrophil MR induces MMP-9 
production, which may promote atherosclerotic plaque rupture.
and thromboxane in the presence and absence of hypertension. 
Taken together, these data support the concept that in healthy 
endothelium, Aldo induces vasodilation, whereas in the setting 
of cardiovascular risk factors, including obesity, diabetes, and 
hypertension, MR in the endothelium contributes to endothelial 
damage and the resulting impairment of endothelial-dependent 
vasodilation.
vascular MR and Aldo in the Development 
of vascular inflammation
MR Contributes to Systemic inflammation in 
Response to Cardiovascular Risk Factors
Cardiovascular risk factors are associated with increased vas-
cular inflammation, and Aldo and the MR have recently been 
implicated in this process. In patients with untreated essential 
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hypertension, higher Aldo levels were associated with increased 
serum inflammatory and pro-thrombotic markers (26). Similarly, 
in obese young adults, high Aldo levels correlated with increased 
serum inflammatory markers and increased aortic stiffness, a risk 
factor for ischemic events (27). In the ApoE−/− mouse athero-
sclerosis model, Aldo treatment increased circulating cytokines 
RANTES and MCP-1 and increased spleen size (13), and in a rat 
model of peritoneal dialysis, spironolactone treatment attenuated 
peritoneal inflammation and fibrosis by decreasing expression 
of MCP-1 and TGF-β (28). Overall, ample data support a link 
between MR activation and the development of inflammation in 
the setting of cardiovascular risk factors (Figure 1).
One mechanism by which Aldo and the MR promote inflam-
mation is by activation of the nuclear factor (NF)κB transcription 
factor, a critical regulator of cytokine and inflammatory gene 
expression [reviewed in Ref. (29)]. In primary cultured rat renal 
collecting duct cells, Aldo-induced NFκB activity and transcrip-
tion of pro-inflammatory cytokines by a mechanism that required 
the classical MR genomic target, serum and glucocorticoid regu-
lated kinase-1 [SGK-1 (30)]. In the vasculature of spontaneously 
hypertensive rats, expression of inflammatory markers IL-1β and 
IL-6 and the NFκB subunit p105 were increased and the NFκB 
inhibitor IκB was decreased compared to normotensive rats. The 
upregulation of NFκB and inflammatory markers was reversed by 
eplerenone but not by triple antihypertensive therapy, suggesting 
that the inflammation was due to MR activity rather than simply 
hypertension (31). Additionally, Aldo treatment of rat vascular 
SMCs induced NFκB translocation to the nucleus resulting in 
dose-dependent increases in cyclooxygenase-2 (COX-2) pro-
tein abundance and IL-6 mRNA transcripts. IL-6 and COX-2 
levels decreased with the addition of inhibitors of the MR or of 
NFκB, confirming that SMC–MR activation by Aldo promotes 
inflammatory gene expression by NFκB activation. Aldo may 
also contribute to SMC inflammatory gene expression through 
a non-genomic mechanism involving activation of the MAP-
kinase/ERK pathway (32). Altogether, these studies demonstrate 
a role for Aldo and the MR in the development of systemic and 
vascular inflammation through the downstream actions of NFκB 
(Figure 2).
MR Contributes to vascular Leukocyte Adhesion 
and Trans-endothelial Migration
When damaged, ECs produce cytokines and express adhesion 
molecules on their surface to attract circulating leukocytes. 
Specifically, activated ECs express P- and E-selectin, intracel-
lular adhesion molecule (ICAM)-1, and vascular cell adhesion 
molecule (VCAM)-1, which interact with leukocyte surface pro-
teins to promote leukocyte–endothelial adhesion and facilitate 
trans-endothelial migration of leukocytes into the vasculature 
[reviewed in Ref. (2)]. Aldo and the MR have been found to 
contribute to this process through effects both in the vasculature 
and in immune cells. In ApoE−/− mice, Aldo treatment enhanced 
aortic leukocyte infiltration (13). In the same study, conditioned 
media from Aldo-treated SMCs promoted monocyte chemotaxis 
in vitro, suggesting a role for SMC–MR in leukocyte recruitment 
to atherosclerotic lesions. In primary human coronary ECs, 
MR activation increased ICAM-1 gene transcription, resulting 
in increased ICAM-1 surface protein, and ICAM-1-dependent 
leukocyte adhesion to human coronary ECs (33). Recently, estro-
gen acting through the estrogen receptor was found to inhibit 
MR induction of ICAM-1 expression in ECs and the associated 
leukocyte adhesion, providing a potential mechanism for sex 
differences in atherosclerosis in pre-menopausal women (34). 
ICAM-1 upregulation by MR in rat mesangial cells was found to 
be mediated by SGK-1-induced phosphorylation and inactivation 
of the NFκB inhibitor IκB, thereby allowing NFκB translocation 
to the nucleus to regulate ICAM-1 transcription (35). Kirsch et al. 
(36) later showed that treatment of human umbilical vein ECs 
with Aldo caused a rearrangement of F-actin cytoskeletal fibers 
and a subsequent increase in trans-endothelial permeability to 
labeled albumin in an MR- and MAPK/ERK-dependent manner. 
This effect of the MR on endothelial permeability could represent 
a mechanism by which the MR contributes to immune cell migra-
tion into the sub-endothelial space early in atherogenesis. Overall, 
these data support that MR activation in human SMCs and ECs 
may directly contribute to vascular inflammation by enhanc-
ing immune cell recruitment, adhesion, and trans-endothelial 
extravasation (Figure 1).
MR effects on inflammatory Cell Function in 
Atherosclerosis
In addition to direct effects on the vasculature, Aldo and MR may 
directly modulate leukocyte function [reviewed in Ref. (37)] to 
contribute to inflammation and atherosclerosis. In ApoE−/− mice, 
eplerenone treatment reduced plaque size, macrophage infiltra-
tion, and oxidative stress (38). Moreover, peritoneal macrophages 
from eplerenone-treated ApoE−/− mice had reduced capacity to 
oxidize low-density lipoprotein and to release superoxide ion 
(14), suggesting that MR may directly modulate macrophage 
function within the plaque. Indeed, macrophages from mice 
with MR genetically deleted from myeloid cells showed changes 
in gene expression profiles consistent with the non-classical M2 
phenotype. These mice were also protected from hypertension-
induced cardiac fibrosis and hypertrophy (39). In  vitro, MR 
activation in macrophages promoted the M1 phenotype and MR 
deletion promoted M2 predominance (39, 40).
T-cell function also plays a role in atherosclerotic plaque 
inflammation and may be modulated by the MR. MR activation 
via fludrocortisone administration to healthy human subjects 
reduced the numbers of circulating naïve CD4+ and CD8+ T-cells 
and increased T-cell expression of CXCR4, a bone marrow-
homing receptor, and CD26L and CCR7, proteins involved in 
migration to lymph nodes (41). Induction of hypertension in 
rats by deoxycorticosterone acetate and salt to activate the MR 
resulted in an increase in the Th17 subset of T-cells as evidenced 
by increased IL-17 and decreased forkhead box P3 expression in 
peripheral blood, heart, and kidney. This effect was reversed by 
treatment with spironolactone, suggesting a role for the MR in 
Th17 cell activation in the setting of hypertension (42), although 
this may be through MR action in dendritic cells rather than in 
T-cells (43).
Finally, the MR may also modulate neutrophil function, with 
potential effects on plaque stability. Treatment of human neutro-
phils with Aldo induced a dose-dependent increase in MMP-9 
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mRNA, which was attenuated by addition of spironolactone or 
of PI3K and ERK pathway inhibitors, implicating the MR and 
PI3K/ERK signaling in Aldo induction of neutrophil MMP-9 
expression (44). Thus, Aldo and MR may also contribute to the 
pathogenesis and adverse outcomes of atherosclerosis by direct 
effects on leukocytes to promote macrophage ROS production 
and M1 polarization, modulate T-cell surface marker expression 
and Th17 differentiation, and increase neutrophil matrix protease 
expression (Figure 1).
MR and Aldo in Plaque Rupture and 
Thrombus Formation
Although stable atherosclerotic plaques can cause symptoms, 
such as angina or claudication, morbidity and mortality is 
predominantly due to plaque rupture causing acute vessel occlu-
sion, tissue ischemia and necrosis, resulting in MI, stroke, limb 
ischemia, and cardiovascular death. Plaque rupture occurs when 
the plaque fibrous cap is sufficiently degraded by MMPs to frac-
ture and expose the thrombogenic core, resulting in activation 
of the clotting cascade. The role of the MR in the rupture and 
thrombosis of atherosclerotic plaques is poorly studied, partly 
due to a lack of rodent models of plaque rupture. MR activation 
has been shown to produce plaques with increased lipids and 
inflammatory cells, a phenotype more prone to rupture (13, 45), 
FiGURe 2 | Mineralocorticoid receptor contributes to vascular inflammation by activation of nFκB. (A) In whole aorta samples, Aldo acting through the 
MR upregulates the expression of NFκB precursor subunit p105 and downregulates the NFκB inhibitor IκB, promoting transcription of cytokines IL-6, IL-1β, and 
TNFα. (B) In ECs, inhibition of the MR with eplerenone attenuates expression of NFκB targets ICAM-1, VCAM, and P-selectin (triangles). In rat mesangial cells, 
regulation of NFκB by the MR was mediated by SGK-1 inhibition of IκB. (C) Aldo exerts both genomic and non-genomic effects on NFκB target genes in SMCs.
and as described above, the MR in neutrophils may contribute 
to MMP expression that destabilizes plaques. There is also some 
evidence that Aldo and the MR contribute to thrombosis. Aldo 
increased the rate of carotid artery thrombosis after thermal 
injury in the LDL-receptor-KO mouse model of atherosclerosis 
(46). In a rat model of thrombosis by vena cava ligation, acute 
Aldo administration enhanced thrombus burden, an effect that 
was prevented by co-treatment with eplerenone (47). Eplerenone 
also reduced post-carotid injury thrombosis in streptozotocin-
induced diabetic rats (48). Aldo treatment has been shown 
to decrease bleeding time (49), induce platelet activation and 
degranulation, and increase expression of the thrombogenic plas-
minogen activator inhibitor [PAI-1 (50)], whereas MR inhibitors 
increase bleeding time (49), decrease platelet activation (50, 51), 
and inhibit expression of PAI-1, fibrinogen, P-selectin, and IL-1β 
in a variety of rodent models (48, 51, 52). Paradoxically, Ducros 
et al. (53) treated cultured human bone marrow ECs with Aldo 
and found an increase in the synthesis of the anti-thrombogenic 
endothelial protein C receptor (EPCR) and an increase in the 
clotting time of isolated plasma exposed to these ECs. Lagrange 
et  al. (54) similarly found that a mouse model overexpressing 
human MR in ECs had increased EPCR expression and a decrease 
in thrombin at the EC surface in vitro. It is possible that rather 
than the traditional anti-thrombogenic protein C pathway, 
these latter findings could represent activation of the alternate 
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cytoprotective pathway, which includes anti-inflammatory, anti-
apoptotic, and gene expression effects [reviewed in Ref. (55)] 
and thus may represent a compensatory mechanism for adverse 
effects of global Aldo treatment, rather than an anti-thrombotic 
effect of Aldo. Overall, although MR appears to play some role 
in vascular thrombogenesis, additional studies are needed to 
clarify the molecular mechanisms, and whether this is relevant 
to thrombosis in the setting of atherosclerotic plaque rupture 
remains to be determined.
Summary and Future Directions
In summary, recent data support that the MR plays a role in 
every step in the development and complications of atheroscle-
rosis, including (1) development of endothelial dysfunction and 
systemic inflammation in response to cardiovascular risk factors; 
(2) EC and SMC production of cytokines and surface expression 
of leukocyte adhesion molecules, resulting in recruitment, adhe-
sion, and transmigration of leukocytes from the circulation to 
the vasculature; (3) leukocyte activation, oxidative stress, and 
MMP expression; (4) development of plaque instability; and (5) 
vascular thrombosis (Figure 1). The many roles of MR in the 
development of atherosclerosis suggest potential novel thera-
pies, including systemic MR inhibition, with currently available 
drugs or targeting of pathways downstream of vascular and 
leukocyte MR to prevent atherosclerosis complications, such 
as MI and stroke. The MR promotes vascular inflammation 
through the NFκB pathway in ECs and SMCs, although other 
pathways, including MAPK/ERK, are involved (Figure  2). 
Further exploration of the role of vascular and leukocyte MR 
in vascular inflammation and leukocyte function are needed to 
identify novel therapeutic targets downstream of MR activation. 
Finally, the interplay between the many cell types involved in 
atherosclerotic lesion development and its complications and 
the role of the MR in this interaction is an important area for 
future study.
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